This inventor holds 3 USPTO granted patents. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1994-1996.
Company Filing History:
Years Active: 1994-1996
Title: Michiko Yamayoshi: Innovator in Biomedical Research
Introduction
Michiko Yamayoshi is a prominent inventor based in Toyonaka, Japan. She has made significant contributions to the field of biomedical research, particularly in the treatment of microbial infections and sarcoma. With a total of 3 patents to her name, her work has the potential to impact the medical community significantly.
Latest Patents
Yamayoshi's latest patents focus on innovative treatments using interleukin 1 polypeptides. The first patent addresses the treatment of microbial infections with interleukin 1 polypeptides, detailing the DNAs encoding these polypeptides, vectors inserted with said DNAs, and hosts transformed with recombinant vectors. It also covers the production of polypeptides with interleukin 1 activity through the cultivation of transformed hosts, along with their derivatives and pharmaceutical compositions. These compositions are proposed for use as antitumor or anti-infectious agents. The second patent similarly targets sarcoma treatment using interleukin 1.alpha. polypeptides, encompassing the same methodologies and applications as her first patent.
Career Highlights
Yamayoshi is currently affiliated with Dainippon Pharmaceutical Company, Limited, where she continues her research and development efforts. Her work has garnered attention for its innovative approach to treating serious health conditions, showcasing her dedication to advancing medical science.
Collaborations
Throughout her career, Michiko Yamayoshi has collaborated with notable colleagues, including Junichi Yamagishi and Masaaki Yamada. These partnerships have contributed to her success and the advancement of her research initiatives.
Conclusion
In summary, Michiko Yamayoshi is a trailblazer in the field of biomedical research, with a focus on innovative treatments for microbial infections and sarcoma. Her contributions through her patents and collaborations highlight her commitment to improving healthcare outcomes.